Clinical trials · Massachusetts
Aspiration clinical trials in Massachusetts
We’re tracking 37 recruiting aspiration studies with a site in Massachusetts — including Phase 1, Phase 2, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies in Massachusetts
- NCT05108896Recruiting
Testing breathing and swallowing recovery after ICU breathing support
This study looks at aspiration (food or liquid going “the wrong way” into the airway) in people who survived a serious ICU breathing problem. It may help doctors better support safe swallowing and breathing recovery after being on a breathing machine.
Boston, MassachusettsAges 18 years+ - NCT06003101RecruitingPhase 3
Blood treatments for hip labrum tear surgery
This study tests whether adding platelet-rich plasma (a blood concentrate), platelet-poor plasma, or bone marrow concentrate during hip surgery helps people with a torn labrum recover better. If you need hip arthroscopy and haven't had prior hip surgery, you may be able to join.
Boston, MassachusettsAges 18 years+ - NCT06747117Recruiting
Removing blood clots in leg arteries with the Indigo system
This study tests a device that vacuums out blood clots from blocked leg arteries, potentially restoring blood flow without open surgery.
Worcester, MassachusettsAges 18 years+ - NCT05674643Recruiting
Gastric testing during children’s surgery
This trial studies how the stomach is working in children around the time of surgery. It may help improve how doctors assess and manage stomach function to make surgery safer and more comfortable.
Boston, MassachusettsAges 2–18 - NCT05455359RecruitingPhase 4
Tube-fed children at high risk for aspiration pneumonia
This Phase 4 study looks at gastrointestinal movement (dysmotility) and how it may increase the risk of aspiration pneumonia in children who eat through a tube and have swallowing safety problems. It may help doctors better prevent lung infections in children who cough/choke and need suction often.
Boston, MassachusettsAges 5–21 - NCT04798261Recruiting
Long-term follow-up after clot removal for pulmonary embolism
This study tracks how patients do long-term after having a clot in the lung treated with a device called the Indigo Aspiration System. It aims to better understand safety and outcomes over time.
Fall River, MassachusettsAges 18 years+ - NCT07466316RecruitingPhase 3
Comparing chemo schedules for intermediate-risk rhabdomyosarcoma
This trial compares two different chemotherapy schedules for children and young adults with intermediate-risk rhabdomyosarcoma (a type of muscle cancer). One group gets a higher dose of chemotherapy over a shorter period, while the other gets a lower dose plus maintenance therapy for a longer time. The goal is to see which approach works better.
Boston, MassachusettsAges Up to 50 years - NCT07321652RecruitingPhase 3
Sonrotoclax plus zanubrutinib for untreated CLL or SLL
This trial tests whether adding a new drug, sonrotoclax, to the standard treatment zanubrutinib works better for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who haven't had treatment before. It's for patients aged 65 and older who need therapy due to symptoms or blood cell issues.
Boston, MassachusettsAges 65 years+ - NCT07303738RecruitingPhase 4
Testing bile-lowering foods for kids with feeding tubes
This trial tests if certain foods can lower bile acid levels in the upper part of the stomach for children who get most nutrition through a feeding tube. It may help understand and manage reflux symptoms related to bile.
Boston, MassachusettsAges 5–21 - NCT07022951Recruiting
Million Anesthesia Cases Study on Preoperative Fasting
This study looks at how fasting before anesthesia affects recovery for people having procedures. Researchers want to understand what happens to patients when they have nothing to eat or drink before anesthesia.
Boston, MassachusettsAges Any age - NCT06917911RecruitingPhase 2
Testing two drug additions to standard chemotherapy for a type of acute myeloid leukemia
This trial tests whether adding venetoclax or gemtuzumab ozogamicin to the usual chemotherapy helps people with a specific genetic type of acute myeloid leukemia (AML) respond better. It may improve chances of remission.
Boston, MassachusettsAges 18–59 - NCT06751043Recruiting
Testing if fasting before a procedure is needed in ICU patients
This trial tests whether not eating before a procedure (called preoperative fasting) is better than fasting in ICU patients who are already receiving tube feedings. It aims to find out if skipping the fast can help you without causing extra risks.
Worcester, MassachusettsAges 18 years+ - NCT06672146RecruitingPhase 2
New treatments for AML with an IDH2 mutation
This trial tests new treatments for people with newly diagnosed acute myeloid leukemia (AML) that has a change in the IDH2 gene. It aims to find a better option for those who cannot have standard high-dose chemotherapy.
Boston, MassachusettsAges 18 years+ - NCT06577441RecruitingPhase 2
Adding enasidenib to usual care for higher-risk MDS with IDH2 mutation
This trial tests whether adding enasidenib (a targeted pill) to the standard chemotherapy (cedazuridine-decitabine) works better than the chemotherapy alone for people with higher-risk myelodysplastic syndrome (MDS) whose cells have a specific change in the IDH2 gene.
Boston, MassachusettsAges 18 years+ - NCT06484062RecruitingPhase 1
Testing cirtuvivint alone and with ASTX727 for leukemia and MDS
This trial tests a new drug called cirtuvivint, given alone or with another drug (ASTX727), for people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) that has come back or not responded to treatment, and for people with high-risk MDS who have not been treated before. The goal is to see if these combinations work better than current options.
Boston, MassachusettsAges 18 years+ - NCT06317649RecruitingPhase 2
Venetoclax with hypomethylating agents for older or unfit adults with FLT3-mutated AML
This trial tests a combination of medicines (venetoclax and a hypomethylating agent) for people with acute myeloid leukemia (AML) who have a FLT3 mutation. It may be an option for older adults or those who cannot tolerate intensive chemotherapy.
Boston, MassachusettsAges 18 years+ - NCT06317662RecruitingPhase 2
Adding venetoclax and blinatumomab to chemo for infant leukemia
This trial tests adding two newer medicines (venetoclax and blinatumomab) to standard chemotherapy for infants with a specific type of leukemia. The goal is to see if this combination helps more babies stay cancer-free.
Boston, MassachusettsAges Up to 12 months - NCT06247787RecruitingPhase 1
Imetelstat plus chemo for relapsed leukemia in kids
This trial tests a new drug called imetelstat combined with two chemotherapy drugs (fludarabine and cytarabine) for children and teens with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or juvenile myelomonocytic leukemia (JMML) that has come back or not responded to treatment. The goal is to find the safest dose of imetelstat and see if it helps control the cancer.
Boston, MassachusettsAges 1–18 - NCT06172296RecruitingPhase 3
Dinutuximab plus transplant for high-risk neuroblastoma
This trial tests adding a targeted drug called dinutuximab to standard chemotherapy, surgery, and a stem cell transplant for children and young adults with a new diagnosis of high-risk neuroblastoma. The goal is to see if this combination helps more patients stay in remission.
Boston, MassachusettsAges Up to 30 years - NCT03909139Recruiting
Stem-cell injection during hip arthroscopy for labral tears
This trial looks at whether using BMAC (a substance made from a person’s own bone marrow) during hip arthroscopy helps people with labral tears caused by hip impingement. It aims to improve hip pain and function by combining the injection with the standard surgical repair.
Boston, MassachusettsAges 18 years+ - NCT06022939RecruitingPhase 3
Comparing chemo plus stem cell transplant to chemo alone for AL amyloidosis
This study tests whether adding a stem cell transplant to standard chemotherapy (Dara-VCD) works better than chemotherapy alone for people newly diagnosed with AL amyloidosis. It aims to find the best way to control the disease and improve outcomes.
Boston, MassachusettsAges 18 years+ - NCT05886049RecruitingPhase 1
Testing a menin drug with standard chemo for newly diagnosed AML
This early-phase study tests a menin inhibitor drug (SNDX-5613) combined with standard induction chemotherapy (daunorubicin plus cytarabine) in newly diagnosed AML with specific gene changes (NPM1 or FLT3 status, or MLL/KMT2A or NUP98). It may help patients whose AML has these genetic features respond better to intensive treatment.
Boston, MassachusettsAges 18–75 - NCT05725967Enrolling by invitation
Endoscopic and bariatric procedures for obesity
This study looks at people who are having obesity-related procedures, including options done with a scope (endoscopic) and revision after prior bariatric surgery. It may help doctors understand outcomes and improve care for people undergoing these treatments.
Boston, MassachusettsAges 18–80 - NCT05554393RecruitingPhase 2
Treating intermediate-risk AML in younger adults
This trial compares three different drug combinations for younger adults (18-59) with intermediate-risk AML. You will be assigned to one of three groups: standard chemotherapy (cytarabine + daunorubicin), that same chemotherapy plus venetoclax, or venetoclax combined with azacitidine.
Boston, MassachusettsAges 18–59
Aspiration trials by city in Massachusetts
Where these studies are running in Massachusetts
Institutions with a site for the recruiting aspiration studies listed above.
- Dana-Farber Cancer Institute · 10 studies
- Tufts Medical Center · 6 studies
- Boston Children's Hospital · 3 studies
- Brigham and Women's Hospital · 2 studies
- Lahey Hospital and Medical Center · 2 studies
- Lahey Medical Center Peabody · 2 studies
- Massachusetts General Hospital · 2 studies
- UMass Memorial Medical Center - University Campus · 2 studies
What taking part in a aspiration study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Common questions
- Are there aspiration clinical trials in Massachusetts?
- Yes. We're currently tracking 37 recruiting aspiration studies with a site in Massachusetts, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a aspiration study in Massachusetts?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Massachusetts to take part?
- Not necessarily. These studies have a site in Massachusetts, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a aspiration trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New aspiration studies open in Massachusetts regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.